RxDoctor Payments DataLook up a doctor →

Raj Satkunasivam

Urology · Houston, TXNPI 1134551278

Payments from drug & device makers

$2,553,699in general payments, 2019–2025

Across 290 payments — averaging $8805.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.2M
  • Pfizer$534K
  • Janssen Research & Development, LLC$393K
  • E.r. Squibb & Sons, L.L.C.$184K
  • Urogen Pharma, Inc.$150K
  • QED Therapeutics, Inc.$44K
  • plus $58K from 31 others
$1,270in research payments, 2019–2025

Across 2 payments — averaging $635.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$1K

What the payments were for

  • Consulting fees$10,56738%
  • Speaking & faculty fees$1,5005%
  • Travel & lodging$3,66213%
  • Food & beverage$2,83410%
  • Education$9,51434%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,553,699 in reported general payments places this provider in the 95th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$172,939
Medicare patients
236
Services billed
4,374

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Docetaxel23$25,263
Gemcitabine Hcl26$3,576
Tamsulosin Hcl134$2,129
Finasteride30$440
Ciprofloxacin Hcl62$254
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst16$204
Sodium Chloride0.9 % Sodium Chloride14$188
Tramadol Hcl49$70
Amlodipine Besylate12$3
Metformin Hcl ErMetformin Hcl11$0

Paid to pharmacies, not to this prescriber.

Other urology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →